{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:40:02Z","timestamp":1721349602811},"reference-count":80,"publisher":"AACN Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,15]]},"abstract":"<jats:p>Evaluating, diagnosing, and managing patients with consumptive thrombocytopenia is challenging because of the overlapping nature of many of the diseases that reduce platelet counts. Immune thrombocytopenia (and its variations), drug-induced immune thrombocytopenia, and heparin-induced thrombocytopenia result from autoimmune antibody-mediated destruction of platelets. Thrombotic thrombocytopenia (both congenital and acquired) and the hemolytic uremic syndromes (both typical and atypical) are thrombotic microangiopathies associated with platelet aggregation and consumption along with anemia and renal dysfunction. Rapid history taking, physical assessment, and laboratory evaluation are crucial to accurately managing patients with these disorders. Platelet-associated coagulopathies are infrequently encountered by most providers, and limited exposure to these types of patients, combined with the wide variety of treatment options for reversing bleeding or thrombotic sequelae, makes management difficult. This article reviews the pathophysiology, patient presentation, diagnostic testing, and specific management strategies and challenges of these thrombocytopenias.<\/jats:p>","DOI":"10.4037\/aacnacc2019186","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:06:16Z","timestamp":1559347576000},"page":"165-180","source":"Crossref","is-referenced-by-count":1,"title":["Management of Select Thrombocytopenias"],"prefix":"10.4037","volume":"30","author":[{"given":"Thomas A.","family":"VanDruff","sequence":"first","affiliation":[{"name":"Thomas A. VanDruff is Critical Care Nurse Practitioner, PMA Health at the Virginia Hospital Center, 1625 North George Mason Drive, Arlington, VA 22205 ()."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2471","reference":[{"issue":"9","key":"2019112612202710400_b1-0300165","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMra1208626","article-title":"Bleeding and coagulopathies in critical care","volume":"370","author":"Hunt","year":"2014","journal-title":"N Engl J Med"},{"key":"2019112612202710400_b2-0300165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13613-014-0024-x","article-title":"Mechanisms and etiologies of thrombocytopenia in the intensive care unit: impact of extensive investigations","volume":"4","author":"Antier","year":"2014","journal-title":"Ann Intensive Care"},{"key":"2019112612202710400_b3-0300165","first-page":"298","article-title":"Alterations in hemostasis and blood coagulation","volume-title":"Pathophysiology","author":"Rockwell","year":"2019","edition":"6th"},{"key":"2019112612202710400_b4-0300165","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/B978-0-323-35762-3.00028-7","article-title":"Thrombocytopoiesis","volume-title":"Hematology: Basic Principles and Practice","author":"Cantor","year":"2018","edition":"7th"},{"key":"2019112612202710400_b5-0300165","first-page":"1","article-title":"Basics of coagulation","volume-title":"Hemostasis and Thrombosis","author":"DeLoughery","year":"2015","edition":"3rd"},{"key":"2019112612202710400_b6-0300165","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/B978-0-323-35762-3.00131-1","article-title":"Diseases of platelet number: immune thrombocytopenia, neonatal alloimmune thrombocytopenia, and posttransfusion purpura","volume-title":"Hematology: Basic Principles and Practice","author":"Arnold","year":"2018","edition":"7th"},{"key":"2019112612202710400_b7-0300165","first-page":"127","article-title":"Platelets","volume-title":"Hematology: A Pathophysiologic Approach","author":"Hudnall","year":"2012"},{"issue":"suppl 1","key":"2019112612202710400_b8-0300165","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1002\/pbc.24341","article-title":"Positioning new treatments in the management of immune thrombocytopenia","volume":"60","author":"Arnold","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2019112612202710400_b9-0300165","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/B978-0-323-35762-3.00128-1","article-title":"Clinical approach to the patient with bleeding or bruising","volume-title":"Hematology: Basic Principles and Practice","author":"Hayward","year":"2018","edition":"7th"},{"key":"2019112612202710400_b10-0300165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-3-319-09312-3_2","article-title":"Tests of hemostasis and thrombosis","volume-title":"Hemostasis and Thrombosis","author":"DeLoughery","year":"2015","edition":"3rd"},{"issue":"2","key":"2019112612202710400_b11-0300165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/imt-2018-0165","article-title":"Safety and efficacy of intravenous immunoglobulin (Flebogamma 10% DIF) in patients with immune thrombocytopenic purpura","volume":"11","author":"Apte","year":"2019","journal-title":"Immunotherapy"},{"issue":"1","key":"2019112612202710400_b12-0300165","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.14515","article-title":"State of the art\u2014how I manage immune thrombocytopenia","volume":"177","author":"Cooper","year":"2017","journal-title":"Br J Haemotol"},{"issue":"1","key":"2019112612202710400_b13-0300165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.seminhematol.2014.10.006","article-title":"Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists","volume":"52","author":"Rodeghiero","year":"2015","journal-title":"Semin Hematol"},{"key":"2019112612202710400_b14-0300165","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1046\/j.1365-2141.2003.04131.x","article-title":"Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy","volume":"120","author":"Allford","year":"2003","journal-title":"Br J Haematol"},{"issue":"3","key":"2019112612202710400_b15-0300165","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/jth.12813","article-title":"Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review","volume":"13","author":"Neunert","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2019112612202710400_b16-0300165","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-3-319-09312-3_11","article-title":"Immune thrombocytopenia","volume-title":"Hemostasis and Thrombosis","author":"DeLoughery","year":"2015","edition":"3rd"},{"issue":"5","key":"2019112612202710400_b17-0300165","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMra043442","article-title":"Diagnosis from the blood smear","volume":"353","author":"Bain","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"2019112612202710400_b18-0300165","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.14423","article-title":"Guidelines for the use of platelet transfusions","volume":"176","author":"Estcourt","year":"2017","journal-title":"Br J Haematol"},{"issue":"6","key":"2019112612202710400_b19-0300165","first-page":"719","article-title":"Transfusion of blood and blood products: indications and complications","volume":"83","author":"Sharma","year":"2011","journal-title":"Am Fam Physician"},{"issue":"9","key":"2019112612202710400_b20-0300165","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood-2014-10-605493","article-title":"Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality","volume":"125","author":"Goel","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019112612202710400_b21-0300165","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2015-07-659656","article-title":"High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial","volume":"127","author":"Wei","year":"2016","journal-title":"Blood"},{"issue":"16","key":"2019112612202710400_b22-0300165","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019112612202710400_b23-0300165","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","article-title":"Clinical updates in adult immune thrombocytopenia","volume":"129","author":"Lambert","year":"2017","journal-title":"Blood"},{"key":"2019112612202710400_b24-0300165","doi-asserted-by":"publisher","first-page":"e024427","DOI":"10.1136\/bmjopen-2018-024427","article-title":"Trial protocol: a multicentre randomized trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial","volume":"8","author":"Pell","year":"2018","journal-title":"BMJ Open"},{"issue":"7","key":"2019112612202710400_b25-0300165","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/trf.13628","article-title":"An evaluation of overall effectiveness and treatment satisfaction with intravenous immunoglobulin among patients with immune thrombocytopenia","volume":"56","author":"Sholapur","year":"2016","journal-title":"Transfusion"},{"issue":"6","key":"2019112612202710400_b26-0300165","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jaci.2008.08.033","article-title":"Intravenous immunoglobulin: adverse reactions and management","volume":"122","author":"Bonilla","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"2019112612202710400_b27-0300165","first-page":"57","article-title":"Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia","volume":"3","author":"Cheung","year":"2009","journal-title":"Biologics"},{"issue":"7","key":"2019112612202710400_b28-0300165","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"9","key":"2019112612202710400_b29-0300165","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019112612202710400_b30-0300165","doi-asserted-by":"crossref","first-page":"408","DOI":"10.7196\/SAMJ.8987","article-title":"Role of splenectomy for immune thrombocytopenic purpura (ITP) in the era of new second-line therapies and in the setting of a high prevalence of HIV-associated ITP","volume":"105","author":"Antel","year":"2015","journal-title":"S Afr Med J"},{"issue":"2","key":"2019112612202710400_b31-0300165","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/21645515.2017.1264797","article-title":"Recommended vaccinations for asplenic and hyposplenic adult patients","volume":"13","author":"Bonani","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2019112612202710400_b32-0300165","doi-asserted-by":"publisher","first-page":"1316096","DOI":"10.1155\/2018\/1316096","article-title":"Efficacy and safety of the combination treatment of rituximab and dexamethasone for adults with primary immune thrombocytopenia (ITP): a meta-analysis","volume":"2018","author":"Wang","year":"2018","journal-title":"Biomed Res Int"},{"issue":"20","key":"2019112612202710400_b33-0300165","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019112612202710400_b34-0300165","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12185-015-1837-6","article-title":"Integrated analysis of long-term safety in patients with chronic immune thrombocytopenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim","volume":"102","author":"Cines","year":"2015","journal-title":"Int J Hematol"},{"issue":"3","key":"2019112612202710400_b35-0300165","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","article-title":"Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study","volume":"121","author":"Saleh","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019112612202710400_b36-0300165","doi-asserted-by":"crossref","DOI":"10.1182\/hem.V15.4.8728","article-title":"Emerging therapies in immune thrombocytopenia","volume":"15","author":"Despotovic","year":"2018","journal-title":"The Hematologist"},{"issue":"29","key":"2019112612202710400_b37-0300165","doi-asserted-by":"publisher","first-page":"e7561","DOI":"10.4037\/MD.0000000000007561","article-title":"Thrombocytopenia in pregnancy with different diagnoses: differential clinical features, treatments, and outcomes","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2019112612202710400_b38-0300165","first-page":"55","article-title":"Thrombocytopenia in pregnancy","volume":"11","author":"Ciobanu","year":"2016","journal-title":"Maedica"},{"issue":"1","key":"2019112612202710400_b39-0300165","doi-asserted-by":"publisher","first-page":"e2017019","DOI":"10.4084\/MJHID.2017.019","article-title":"Thrombocytopenia in patients with chronic hepatitis C virus infection","volume":"9","author":"Dahal","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2019112612202710400_b40-0300165","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.pharmthera.2017.10.009","article-title":"Direct antiviral agents (DAAs)\u2014a new age in the treatment of hepatitis C virus infection","volume":"183","author":"Spengler","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"2","key":"2019112612202710400_b41-0300165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1545109712462068","article-title":"Immune thrombocytopenic purpura: a presentation of HIV infection","volume":"12","author":"Shah","year":"2013","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"6","key":"2019112612202710400_b42-0300165","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s10156-013-0588-7","article-title":"Combination of high-dose dexamethasone and antiretroviral therapy rapidly improved and induced long-term remission of HIV-related thrombocytopenic purpura","volume":"19","author":"Shindo","year":"2014","journal-title":"J Infect Chemother"},{"key":"2019112612202710400_b43-0300165","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12878-01809119-y","article-title":"The impact of Helicobacter pylori eradication on platelet counts of adult patients with idiopathic thrombocytopenic purpura","volume":"18","author":"Aljarad","year":"2018","journal-title":"BMC Hematol"},{"issue":"3","key":"2019112612202710400_b44-0300165","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3748\/wjg.v20.i3.665","article-title":"Eradication of Helicobacter pylori infection: which regimen first?","volume":"20","author":"Federico","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2019112612202710400_b45-0300165","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/B978-0-323-35762-3.00132-3","article-title":"Thrombocytopenia caused by platelet destruction, hypersplenism, or hemodilution","volume-title":"Hematology: Basic Principles and Practice","author":"Warkentin","year":"2018","edition":"7th"},{"issue":"6","key":"2019112612202710400_b46-0300165","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1097\/CCM.0b013e3181de0b88","article-title":"Drug-induced thrombocytopenia in critically ill patients","volume":"38","author":"Priziola","year":"2010","journal-title":"Crit Care Med"},{"issue":"6","key":"2019112612202710400_b47-0300165","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1538-7836.2009.03360.x","article-title":"Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management","volume":"7","author":"Aster","year":"2009","journal-title":"J Thromb Haemost"},{"key":"2019112612202710400_b48-0300165","unstructured":"George JN . Drug-induced thrombocytopenia. Platelets on the web. https:\/\/www.ouhsc.edu\/platelets\/ditp.html. Updated May 4, 2015. Accessed December 20, 2018."},{"issue":"11","key":"2019112612202710400_b49-0300165","doi-asserted-by":"crossref","first-page":"886","DOI":"10.7326\/0003-4819-129-11_Part_1-199812010-00009","article-title":"Drug-induced thrombocytopenia: a systematic review of published case reports","volume":"129","author":"George","year":"1998","journal-title":"Ann Intern Med"},{"issue":"22","key":"2019112612202710400_b50-0300165","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv"},{"key":"2019112612202710400_b51-0300165","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/B978-0-323-35762-3.00133-5","article-title":"Heparin-induced thrombocytopenia","volume-title":"Hematology: Basic Principles and Practice","author":"Warkentin","year":"2018","edition":"7th"},{"key":"2019112612202710400_b52-0300165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-319-09312-3_22","article-title":"Heparins and heparin-induced thrombocytopenia","volume-title":"Hemostasis and Thrombosis","author":"DeLoughery","year":"2015","edition":"3rd"},{"issue":"8","key":"2019112612202710400_b53-0300165","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMct1206642","article-title":"Nonheparin anticoagulants for heparin-induced thrombocytopenia","volume":"368","author":"Kelton","year":"2013","journal-title":"N Engl J Med"},{"issue":"21","key":"2019112612202710400_b54-0300165","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"issue":"1114","key":"2019112612202710400_b55-0300165","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/postgradmedj-2018-135702","article-title":"Heparin-induced thrombocytopaenia","volume":"94","author":"Prince","year":"2018","journal-title":"Postgrad Med J"},{"issue":"3","key":"2019112612202710400_b56-0300165","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMcp1411910","article-title":"Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"2019112612202710400_b57-0300165","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/bjh.12059","article-title":"Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition","volume":"159","author":"Watson","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"2019112612202710400_b58-0300165","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2006.01787.x","article-title":"Evaluation of pretest clinical score (4 T\u2019s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings","volume":"4","author":"Lo","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2019112612202710400_b59-0300165","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1538-7836.2010.03880.x","article-title":"Non-necrotizing heparin-induced skin lesions and the 4 T\u2019s score","volume":"8","author":"Warkentin","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"4-5","key":"2019112612202710400_b60-0300165","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.autrev.2014.01.004","article-title":"Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification","volume":"13","author":"Shenkman","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"21","key":"2019112612202710400_b61-0300165","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2019112612202710400_b62-0300165","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"2019112612202710400_b63-0300165","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.mayocp.2016.05.015","article-title":"Thrombotic microangiopathy care pathway: a Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group","volume":"91","author":"Go","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"2019112612202710400_b64-0300165","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/jth.13716","article-title":"Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura","volume":"15","author":"Peyvandi","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2019112612202710400_b65-0300165","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/B978-0-323-35762-3.00134-7","article-title":"Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome","volume-title":"Hematology: Basic Principles and Practice","author":"Schneidenwend","year":"2018","edition":"7th"},{"issue":"4","key":"2019112612202710400_b66-0300165","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"2019112612202710400_b67-0300165","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5858\/arpa.2015-0444-RS","article-title":"The direct antiglobulin test: indications, interpretation, and pitfalls","volume":"141","author":"Parker","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"2019112612202710400_b68-0300165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-319-09312-3_12","article-title":"Thrombotic microangiopathy","volume-title":"Hemostasis and Thrombosis","author":"DeLoughery","year":"2015","edition":"3rd"},{"issue":"23","key":"2019112612202710400_b69-0300165","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/bloodadvances.2017009308","article-title":"Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura","volume":"1","author":"Cataland","year":"2017","journal-title":"Blood Adv"},{"key":"2019112612202710400_b70-0300165","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2019112612202710400_b71-0300165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/rth2.12066","article-title":"Novel therapies in thrombotic thrombocytopenic purpura","volume":"2","author":"Masias","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"2019112612202710400_b72-0300165","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"key":"2019112612202710400_b73-0300165","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2018-99-110656","article-title":"Predictors of relapse and efficacy of rituximab in autoimmune thrombotic thrombocytopenic purpura (TTP): a multi-institutional registry-based analysis","volume":"132","author":"Sun","year":"2018","journal-title":"Blood"},{"key":"2019112612202710400_b74-0300165","unstructured":"A phase 3, randomized, controlled study of prophylactic and on-demand treatment of cTTP with BAX 930 (rADAMTS13). ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03393975. Updated March 23, 2018. Accessed January 5, 2019."},{"issue":"10","key":"2019112612202710400_b75-0300165","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/jth.13764","article-title":"Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis, and potential novel therapeutics","volume":"15","author":"Saha","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"21","key":"2019112612202710400_b76-0300165","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2016-11-709865","article-title":"HUS atypical HUS","volume":"129","author":"Jokiranta","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019112612202710400_b77-0300165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12959-016-0114-0","article-title":"Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome","volume":"14","author":"Shen","year":"2016","journal-title":"Thromb J"},{"issue":"2","key":"2019112612202710400_b78-0300165","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.RV17026","article-title":"Pathogenesis of atypical uremic syndrome","volume":"26","author":"Yoshida","year":"2019","journal-title":"J Atheroscler Thromb"},{"issue":"23","key":"2019112612202710400_b79-0300165","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2019112612202710400_b80-0300165","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pcl.2018.09.011","article-title":"Hemolytic uremic syndrome","volume":"66","author":"Cody","year":"2019","journal-title":"Pediatr Clin North Am"}],"container-title":["AACN Advanced Critical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/aacnjournals.org\/aacnacconline\/article-pdf\/30\/2\/165\/117355\/165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/aacnjournals.org\/aacnacconline\/article-pdf\/30\/2\/165\/117355\/165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:05:13Z","timestamp":1721347513000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacnjournals.org\/aacnacconline\/article\/30\/2\/165\/21946\/Management-of-Select-Thrombocytopenias"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,15]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6,15]]}},"URL":"https:\/\/doi.org\/10.4037\/aacnacc2019186","relation":{},"ISSN":["1559-7768","1559-7776"],"issn-type":[{"value":"1559-7768","type":"print"},{"value":"1559-7776","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,15]]}}}